Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation?
Embryonic dopamine cell transplants survive in nearly all patients regardless of age and without immunosuppression. Transplants can improve Parkinson "off" symptoms up to the best effects of L-dopa observed preoperatively. They cannot improve the "best on" state. Transplants appear to survive indefinitely. In 10 to 15% of patients, transplants can reproduce the dyskinetic effects of L-dopa even after discontinuing all L-dopa. Neurotransplantation should be tried earlier in the clinical course of Parkinson's to see if earlier intervention can prevent progression of the disease, particularly the dyskinetic responses seen after longterm L-dopa treatment.
Departments of Medicine, Neurology, Psychiatry, and Neurosurgery Box, University of Colorado School of Medicine, 4200 East Ninth Avenue, C237, Denver, CO 80220, USA. Curt.Freed@uchsc.edu
Curt R
CR
Freed
Maureen A
MA
Leehey
Michael
M
Zawada
Kimberly
K
Bjugstad
Laetitia
L
Thompson
Robert E
RE
Breeze
D001921:Brain / Q000473:pathology / Q000601:surgery; D016380:Brain Tissue Transplantation; D018450:Disease Progression; D004298:Dopamine / Q000378:metabolism; D004311:Double-Blind Method; D004622:Embryo, Mammalian; D016332:Fetal Tissue Transplantation; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D009474:Neurons / Q000637:transplantation*; D010300:Parkinson Disease / Q000188:drug therapy / Q000601:surgery*; D033581:Stem Cell Transplantation / Q000379:methods; D014055:Tomography, Emission-Computed; D019737:Transplants; D016896:Treatment Outcome
D007980:Levodopa; D004298:Dopamine